Pharmacology of acute lung injury

被引：57

作者：

Tasaka, S

Hasegawa, N

Ishizaka, A

机构：

[1] Tokyo Elect Power Co Hosp, Dept Lab Med, Shinjuku Ku, Tokyo 1600016, Japan

[2] Keio Univ, Sch Med, Dept Med, Tokyo 160, Japan

[3] Nippon Kokan KK, Dept Med, Kawasaki, Kanagawa 210, Japan

来源：

PULMONARY PHARMACOLOGY & THERAPEUTICS | 2002年 / 15卷 / 02期

关键词：

ALI/ARDS; sepsis; pharmacological treatment;

D O I：

10.1006/pupt.2001.0325

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is a clinical syndrome that affects both medical and surgical patients. To date, despite improved understanding of the pathogenesis of ALI/ARDS, pharmacological modalities have been unsuccessful in decreasing mortality. However, several pharmacological agents for ARDS are in development and have shown great promise. In addition to the antiinflammatory category including late corticosteroids, inhaled nitric oxide, alveolar surfactant, and vasodilators are being evaluated. Replacements of anticoagulation mediators have also suggested beneficial effects on the patient outcome. This article provides an overview of pharmacological treatments of ALI/ARDS. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

收藏

页码：83 / 95

页数：13

相关论文

共 145 条

[21] EARLY METHYLPREDNISOLONE TREATMENT FOR SEPTIC SYNDROME AND THE ADULT RESPIRATORY-DISTRESS SYNDROME [J].

BONE, RC ;

FISHER, CJ ;

CLEMMER, TP ;

SLOTMAN, GJ ;

METZ, CA .

CHEST, 1987, 92 (06) :1032-1036

[22] Tissue inhibitors of metalloproteinases: evolution, structure and function [J].

Brew, K ;

Dinakarpandian, D ;

Nagase, H .

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1477 (1-2) :267-283

[23] Gene therapy for acute lung injury [J].

Brigham, KL ;

Stecenko, AA .

INTENSIVE CARE MEDICINE, 2000, 26 (Suppl 1) :S119-S123

[24] Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome [J].

Brochard, L ;

Roudot-Thoraval, F ;

Roupie, E ;

Delclaux, C ;

Chastre, J ;

Fernandez-Mondéjar, E ;

Clémenti, E ;

Mancebo, J ;

Factor, P ;

Matamis, D ;

Ranieri, M ;

Blanch, L ;

Rodi, G ;

Mentec, H ;

Dreyfuss, D ;

Ferrer, M ;

Brun-Buisson, C ;

Tobin, M ;

Lemaire, F .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1998, 158 (06) :1831-1838

[25] Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis [J].

Camerota, AJ ;

Creasey, AA ;

Patla, V ;

Larkin, AA ;

Fink, MP .

JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (03) :668-676

[26]

CENEVIVA GD, 1998, AM J PHYSIOL, V185, P601

[27] The efficacy and safety of KL(4)-surfactant in infants with respiratory distress syndrome [J].

Cochrane, CG ;

Revak, SD ;

Merritt, A ;

Heldt, GP ;

Hallman, M ;

Cunningham, MD ;

Easa, D ;

Pramanik, A ;

Edwards, DK ;

Alberts, MS .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 153 (01) :404-410

[28] Surfactant lavage treatment in a model of respiratory distress syndrome [J].

Cochrane, CG ;

Revak, SD .

CHEST, 1999, 116 (01) :85S-86S

[29] INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis [J].

Cohen, J ;

Carlet, J .

CRITICAL CARE MEDICINE, 1996, 24 (09) :1431-1440

[30] PROTECTION OF RABBIT LUNGS FROM ENDOTOXIN INJURY BY IN-VIVO HYPEREXPRESSION OF THE PROSTAGLANDIN G/H SYNTHASE GENE [J].

CONARY, JT ;

PARKER, RE ;

CHRISTMAN, BW ;

FAULKS, RD ;

KING, GA ;

MEYRICK, BO ;

BRIGHAM, KL .

JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (04) :1834-1840

← 1 2 3 4 5 6 7 8 9 10 →